When responding to an ad for a job caring for patient-detainees along the US southern border, applicants should anticipate the need to navigate dual loyalties.
AMA J Ethics. 2021; 23(1):E12-17. doi:
10.1001/amajethics.2021.12.
Streamlining US health care business has raised unique privacy concerns. Bills and explanations of benefits contain protected health information that could be disclosed to someone other than the patient.
AMA J Ethics. 2016; 18(3):279-287. doi:
10.1001/journalofethics.2016.18.3.pfor4-1603.
Financial relationships are common, and ethical questions rightly emerge about how conflicts of interest compromise investigators’ approaches to research.
AMA J Ethics. 2021; 23(9):E685-691. doi:
10.1001/amajethics.2021.685.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"